Proliferating cells, in particular tumor cells, are characterized by a high amount of the dimeric form of the pyruvate kinase isoenzyme type M2 (Tumor M2-PK). Tumor M2-PK can be determined in EDTA ...

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel ...

About PYRUKYND® (mitapivat) PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States, and for the ...

C2C12 myoblasts (ATCC) were cultured in 10% fetal bovine serum (FBS) (Gibco, Australia) in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Waltham, MA, United States) at 37°C and 5% CO 2. The ...

This study provides convincing evidence for functional subpopulations of β-cells responsible for Ca2+ signal initiation and maintenance using novel three-dimensional light sheet microscopy imaging and ...

Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...

William Blair analyst Sami Corwin has maintained their bullish stance on RCKT stock, giving a Buy rating yesterday. Sami Corwin has given his ...

Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma ...

Rocket Pharmaceuticals, Inc. , a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The ...